Though women of childbearing age are diagnosed with myeloproliferative neoplasms (MPNs) less frequently than the general population, it is key that all hematologists are aware of the treatment options available to women with MPNs who are planning to become pregnant or are already pregnant, and work with the patients obstetrician and midwifery group to maximize the chance of a healthy birth. In this interview, Susan Robinson, MBBS, MCRP, MDRes, FRCP, FRCPath, from Guys and St Thomas Hospital NHS Foundation Trust, London, UK, discusses the statistics and risks regarding pregnancy in patients with MPNs, the treatments and precautions typically taken, and how future studies can improve treatment strategies further. This video was recorded at the Myeloproliferative Neoplasms Advances Day 2017, held in London, UK.
Risks and treatments for pregnant MPN patients
